Review of the Current Published Evidence for Single-Dose HPV Vaccination
The cost of the human papillomavirus (HPV) vaccine and its delivery in a multi-dose schedule have created barriers to introduction and program sustainability in low- and middle-income countries, but a single-dose regimen could potentially reduce the costs of vaccine supply and delivery. This report summarizes and assesses the current evidence that could support a change to a single-dose schedule of HPV vaccination. It includes detailed summaries of published evidence; interprets the implications of the results relevant to single-dose HPV vaccine immunogenicity, efficacy, or effectiveness; identifies gaps in the evidence and possible approaches that could fill these gaps; highlights forthcoming data that could contribute to the evidence gaps; and an overall conclusion for the strategic direction needed to inform decisions about HPV single-dose or alternative schedules.
Author: Single-Dose HPV Vaccine Consortium
» Download file (English)
6.29 MB PDF (Located at www.rho.org)
Diseases/vaccines: Human papillomavirus (HPV)